19.5 USD
-0.45 (-2.26%)
19.5 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to ZLAB. ZLAB was compared to 534 industry peers in the Biotechnology industry. ZLAB may be in some trouble as it scores bad on both profitability and health. ZLAB is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ZLAB had negative earnings in the past year.
In the past year ZLAB has reported a negative cash flow from operations.
ZLAB had negative earnings in each of the past 5 years.
ZLAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ZLAB has a Return On Assets of -18.26%. This is in the better half of the industry: ZLAB outperforms 77.53% of its industry peers.
With a decent Return On Equity value of -26.84%, ZLAB is doing good in the industry, outperforming 79.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| ROIC | N/A |
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ZLAB has a better Gross Margin (62.46%) than 78.84% of its industry peers.
ZLAB's Gross Margin has declined in the last couple of years.
ZLAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
2. Health
2.1 Basic Checks
ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZLAB has more shares outstanding than it did 1 year ago.
ZLAB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZLAB has a worse debt to assets ratio.
2.2 Solvency
ZLAB has an Altman-Z score of 0.89. This is a bad value and indicates that ZLAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ZLAB (0.89) is better than 62.73% of its industry peers.
ZLAB has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.22, ZLAB is not doing good in the industry: 66.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.89 |
ROIC/WACCN/A
WACC7.39%
2.3 Liquidity
ZLAB has a Current Ratio of 3.12. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.12, ZLAB is doing worse than 61.98% of the companies in the same industry.
A Quick Ratio of 2.93 indicates that ZLAB has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, ZLAB is not doing good in the industry: 61.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 29.63% over the past year.
Looking at the last year, ZLAB shows a very strong growth in Revenue. The Revenue has grown by 49.59%.
Measured over the past years, ZLAB shows a very strong growth in Revenue. The Revenue has been growing by 98.34% on average per year.
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)49.59%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%
3.2 Future
ZLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 81.52% yearly.
The Revenue is expected to grow by 37.92% on average over the next years. This is a very strong growth
EPS Next Y43.11%
EPS Next 2Y45.32%
EPS Next 3Y52.96%
EPS Next 5Y81.52%
Revenue Next Year41.91%
Revenue Next 2Y46.1%
Revenue Next 3Y44.72%
Revenue Next 5Y37.92%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ZLAB. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 70.59, which means the current valuation is very expensive for ZLAB.
ZLAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. ZLAB is cheaper than 88.20% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.10. ZLAB is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 70.59 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ZLAB's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZLAB's earnings are expected to grow with 52.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.32%
EPS Next 3Y52.96%
5. Dividend
5.1 Amount
No dividends for ZLAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
19.5
-0.45 (-2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners31.3%
Inst Owner Change-10.3%
Ins Owners1.73%
Ins Owner Change20.94%
Market Cap2.16B
Revenue(TTM)398.99M
Net Income(TTM)-212.52M
Analysts78.57
Price Target24.38 (25.03%)
Short Float %4.5%
Short Ratio5.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)15.62%
Min EPS beat(4)-12.04%
Max EPS beat(4)50.98%
EPS beat(8)6
Avg EPS beat(8)16.58%
EPS beat(12)9
Avg EPS beat(12)32.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.38%
Min Revenue beat(2)-14.17%
Max Revenue beat(2)-10.58%
Revenue beat(4)0
Avg Revenue beat(4)-7.13%
Min Revenue beat(4)-14.17%
Max Revenue beat(4)-1.65%
Revenue beat(8)3
Avg Revenue beat(8)-2.39%
Revenue beat(12)5
Avg Revenue beat(12)-2.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-28.25%
PT rev (3m)-32%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-9.42%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)-1.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.47%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)-1.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 70.59 | ||
| P/S | 5.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.72 | ||
| P/tB | 2.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.88
EYN/A
EPS(NY)0.28
Fwd EY1.42%
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS3.87
BVpS7.16
TBVpS6.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.46% | ||
| FCFM | N/A |
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score4
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 425.16% | ||
| Cap/Sales | 13.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | 0.89 |
F-Score4
WACC7.39%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y43.11%
EPS Next 2Y45.32%
EPS Next 3Y52.96%
EPS Next 5Y81.52%
Revenue 1Y (TTM)49.59%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%
Revenue Next Year41.91%
Revenue Next 2Y46.1%
Revenue Next 3Y44.72%
Revenue Next 5Y37.92%
EBIT growth 1Y30.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.23%
EBIT Next 3Y38.79%
EBIT Next 5Y32.27%
FCF growth 1Y39.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.78%
OCF growth 3YN/A
OCF growth 5YN/A
ZAI LAB LTD-ADR / ZLAB FAQ
Can you provide the ChartMill fundamental rating for ZAI LAB LTD-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB.
Can you provide the valuation status for ZAI LAB LTD-ADR?
ChartMill assigns a valuation rating of 2 / 10 to ZAI LAB LTD-ADR (ZLAB). This can be considered as Overvalued.
How profitable is ZAI LAB LTD-ADR (ZLAB) stock?
ZAI LAB LTD-ADR (ZLAB) has a profitability rating of 2 / 10.
What is the expected EPS growth for ZAI LAB LTD-ADR (ZLAB) stock?
The Earnings per Share (EPS) of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 43.11% in the next year.